Ashley Yeo is attached to the medtech titles within Informa’s Pharma intelligence division.
As Health Care editor on In Vivo (monthly hardcopy and online daily services), he writes and commissions news and feature material to meet the strategic business and market access information needs of senior players and device makers as they move innovations into the global medtech market place.
As part of the Principal Analyst team, he also contributes news delivery and insight needs across the group’s other medtech titles in the field of market access (global regulatory, reimbursement, policy changes). Key areas of focus are Germany, the UK and global themes, and EU and other outside global regulatory insight.
A linguist by training, he joined what was later to become Informa in mid-1988 as a French and German news reporter (with some other European languages also in the mix), and has been editor of three of the group’s titles (including Clinica) over a 14-year-period.
These duties are combined with supporting the growing Ask The Analyst service. He says: “This helps us as a group keep a close relationship with long-term and potential subscribers in a sector where insight and knowledge are key to our clients’ commercial success.”
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Ashley Yeo
Cost-recovery requirements have induced regulator Swissmedic to introduce notification fees for lower-risk, class I devices, IVDs and products that use non-viable human tissues, with immediate effect.
On this week's podcast, Ashley Yeo talks about the "Long Term Plan" published by the UK's National Health Service this week, and the implications of Brexit.
The new "NHS Long Term Plan" is an opportunity for an expansive vision in the UK, but it will fall short in its ambitious aims if it merely defaults to old, failed concepts of annualized, silo-nature NHS budgeting. These have proven to be a persistent and significant barrier to the introduction of innovation, says Peter Ellingworth, chief executive of the Association of British HealthTech Industries (ABHI).
The over-running NHS England Long-Term Plan, to be released in full on Jan. 7, was a central discussion theme at the ABHI’s Market Conference last fall, an occasion that marked 30 years of the association’s support for industry. Early indications about the plan are that digital, early diagnosis, long-term and mental health care are among the key themes and challenges that will be addressed, and supported by the five-year funding boost announced last year. But is the cash settlement enough, and does the plan push the right buttons?
The UK health-tech industry association ABHI marked 30 years of supporting local manufacturers and helping the sector adapt to changing needs at a special UK Market Conference in November. The future-facing forum was notable for highlighting the fact that clinicians and the Royal Colleges are increasingly on the same page as industry on how the sector must transform to meet the growing need for affordable, quality health care.
Medtech continues to outperform biotech from a sustainable investment growth point of view, and meanwhile medtech CEOs are on message about advancing value- and outcomes-based models with their provider partners. It all points to medtech being in a good place for 2019, and there is no reason for M&A and industry consolidation to stop anytime soon, says Jefferies equity analyst Raj Denhoy.